Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD)

Eli Lilly and Company announces in a media release that it will present new data from Taltz (ixekizumab), Olumiant (baricitinib), mirikizumab and lebrikizumab at the virtual American Academy of Dermatology (AAD) meeting.